Family Medicine Doctors in Sterling, MA Accepting Medicare
6 Family Medicine doctors found. Showing 1 - 6
 Kathryn Jayne Maier, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 50 Leominster Rd, Sterling, MA 01564 Phone: 978-422-5082 |
Tanvee Uday Dhruva, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 104 Leominster Rd, Sterling, MA 01564 Phone: 978-422-7774 |
Angela M Giza, NP Family Medicine Medicare: Medicare Enrolled Practice Location: 104 Leominster Rd, Sterling, MA 01564 Phone: 978-422-7774 Fax: 978-422-9089 |
Jessica Blanchard, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Leominster Rd, Sterling, MA 01564 Phone: 978-422-7774 |
 Sandeep Kattar, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 50 Leominster Rd, Sterling, MA 01564 Phone: 978-422-5082 Fax: 978-422-5081 |
Dr. Valerie J. Moreland, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 50 Leominster Rd, Sterling, MA 01564 Phone: 978-422-5082 |
News Archive
BioSyent Pharma receives exclusive rights to manufacture and market Virsani sanitizer in Canada and U.S.
BioSyent Inc. ("BioSyent") announces that its subsidiary BioSyent Pharma Inc. has signed a license and distribution agreement with Notlers for VirsaniTM personal sanitizer.
Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.
Addition of S-1 to cisplatin plus radiotherapy ‘favourable' in NSCLC
Research suggests that treatment with cisplatin plus S-1 together with thoracic radiotherapy is relatively efficacious and tolerable in patients with locally advanced non-small-cell lung cancer.
CMS will keep a close eye on 'innovation' funding
Funds for new Medicare experiments - appropriated as part of the health law - may require special scrutiny to ensure they are spent correctly, a Medicare official said, CongressDaily/NextGov reports.
Halozyme Therapeutics receives FDA clearance for Cumulase
Halozyme Therapeutics has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Cumulase for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The active pharmaceutical ingredient in Cumulase is the first and only recombinant human hyaluronidase approved in the United States for cumulus removal in the IVF process.
› Verified 1 days ago